{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreihank45pdcmgh53dshpwfhvjecmu5ddnpisljj3eqmr6q5ax6sioi",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mkj2m5godxa2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreibnidpcvbrzslxd4qbwsdsvjxpv3v23kott7rqikojrl43nlprd7y"
    },
    "mimeType": "image/jpeg",
    "size": 381341
  },
  "path": "/news/2026-04-umbilical-cord-blood-transplant-pooled.html",
  "publishedAt": "2026-04-27T16:00:04.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "A new way of using umbilical cord blood for treating blood diseases could make the treatment more accessible to patients who need a stem cell transplant. A Phase II clinical trial of patients undergoing a cord blood transplant plus a stem cell product derived from pooled cord blood units showed that 27 of 28 patients (96%) with leukemias and myelodysplastic syndrome survived at least one year and none of the patients experienced severe acute or chronic graft-versus-host disease, which are common complications of stem cell transplantation.",
  "title": "Umbilical cord blood transplant with pooled stem cell product shows 96% survival and no GVHD in leukemia patients"
}